GENE ONLINE|News &
Opinion
Blog

Everest, Calliditas Win First Approval for Rare Kidney Disease Drug in Europe

by Joy Lin
Share To

Shanghai-based Everest Medicines has announced the European approval of its rare kidney drug, Kinpegyo. Approval was granted to Everest’s partner, Calliditas Therapeutics, a Swedish biopharma. Developed under the name Nefecon, the drug will be used to treat primary immunoglobulin A (IgA) in nephropathy (IgAN) in high-risk adults with urine protein-to-creatinine ratio (UPCR) ≥1.5 g/gram.

Kinpegyo, an orphan medicine, is the first Europe-approved treatment for IgAN, a rare, progressive autoimmune kidney disease. 50% of patients with this condition may progress to end-stage renal disease. 

The conditional approval will cover all 27 European Union member states as well as Iceland, Norway, and Liechtenstein.

Related article: Everest Medicines Secures Breast Cancer Drug Approval in China

 

Current and Pending Approvals for Kinpegyo (Nefecon

 

The European approval is based on data from the first part of Everest and Calliditas’ pivotal Phase 3 study, NeflgArd. The trial assessed a 16mg, once daily oral dose of Kinpegyo versus placebo in adult primary IgAN patients, and met its primary endpoint in reducing UPCR levels after 9 months of treatment. 

Last December, Nefecon was granted FDA accelerated approval under the brand name Tarpeyo. More recently this April, Everest reported that the drug reduced UPCR and stabilized the eGFR in a Chinese subpopulation in line with the pivotal trial results. The new data will be included in a planned filing for approval of the drug in China in the second half of this year. 

Everest is also pursuing development and commercialization of Nefecon in Singapore and South Korea, where besides kthe Greater China region, it has exclusive rights.  

“Primary IgAN is more common in Asia than elsewhere in the world with even higher unmet demand for innovative treatment and we hope to make this important therapy available in our region soon,” commented Kerry Blanchard, MD, PhD, CEO of Everest Medicines.

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Everest’s Renal Drug Gets Placed On Fast Track For Approval In Taiwan And Korea
2022-11-28
AstraZeneca’s Treatment for Rare Throat Disease, Eosinophilic esophagitis, Fails Primary Endpoint
2022-10-25
Bristol Myers Squibb’ sNDA for Rare Heart Disease Treatment Accepted by the FDA
2022-10-21
LATEST
Rebyota Passes Through FDA To Become First Approved Fecal Microbiota Product
2022-12-05
RemeGen Presented New Data Updates on Telitacicept for SLE and primary Sjogren’s syndrome at ACR Convergence 2022
2022-12-05
EMA Urges Pholcodine’s Removal from European Market Following Safety Study
2022-12-05
Lynk Pharmaceuticals Announces First Patient Dosed in Phase Ⅱ Clinical Study of LNK01003 in Patients with Ulcerative Colitis
2022-12-04
Cure Brain Cancer Foundation Rings Nasdaq Opening Bell, Announces U.S. Expansion
2022-12-02
Focus-X Therapeutics, a Viva Biotech Portfolio Company, Successfully Reached an Acquisition Agreement with Full-Life Technologies
2022-12-02
Pfizer To Invest $1.26 Billion In Irish Plant, Forms New Vant Company Targeting Inflammation
2022-12-02
EVENT
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2022-12-21
Avatar Medicine Forum
Online
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!